Osteoimmunology in rheumatic diseases

Arthritis Research and Therapy

Volumn 11, Issue 1, 2009, Pages

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; AUTOANTIBODY; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR; WNT PROTEIN;

ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; BONE EROSION; BONE MARROW; CELL DIFFERENTIATION; DISEASE COURSE; DRUG MECHANISM; ENCHONDRAL OSSIFICATION; FRAGILITY FRACTURE; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; JOINT DESTRUCTION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; OSSIFICATION; OSTEOCLAST; OSTEOIMMUNOLOGY; OSTEOLYSIS; OSTEOPHYTE; OSTEOPOROSIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ANIMAL; BONE; PATHOPHYSIOLOGY;

ANIMALS; BONE AND BONES; HUMANS; IMMUNE SYSTEM; RHEUMATIC DISEASES;

EID: 60549102695     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2571     Document Type: Review

References (48)

1. Takayanagi H Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems Nat Rev Immunol 2007, 7:292-304. 10.1038/ nri2062 17380158
2. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S Hsu H Sullivan J Hawkins N Davy E Capparelli C Eli A Qian YX Kaufman S Sarosi I Shalhoub V Senaldi G Guo J Delaney J Boyle WJ Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998, 93:165-176. 10.1016/ S0092-8674(00)81569-X 9568710
3. Kong YY Yoshida H Sarosi I Tan HL Timms E Capparelli C Morony S Oliveirados-Santos AJ Van G Itie A Khoo W Wakeham A Dunstan CR Lacey DL Mak TW Boyle WJ Penninger JM OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 1999, 397:315-323. 10.1038/16852 9950424
4. Horwood NJ Kartsogiannis V Quinn JM Romas E Martin TJ Gillespie MT Activated T lymphocytes support osteoclast formation in vitro Biochem Biophys Res Commun 1999, 265:144-150. 10.1006/bbrc.1999.1623 10548505
5. McInnes I Schett G Cytokines in the pathogenesis of rheumatoid arthritis Nat Immunol 2007, 7:429-442. 10.1038/nri2094
6. Firestein GS Evolving concepts of rheumatoid arthritis Nature 2003, 423:356-361. 10.1038/nature01661 12748655
7. Heijde Van der DM Joint erosions and patients with early rheumatoid arthritis Br J Rheumatol 1995, 34:74-78. 8535653
8. Bromley M Woolley DE Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint Arthritis Rheum 1984, 27:968-975. 10.1002/art.1780270902 6236824
9. Gravallese EM Harada Y Wang JT Gorn AH Thornhill TS Goldring SR Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis Am J Pathol 1998, 152:943-951. 1858257 9546355
10. Pettit AR Ji H von Stechow D Müller R Goldring SR Choi Y Benoist C Gravallese EM TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis Am J Pathol 2001, 159:1689-1699. 1867076 11696430
11. Redlich K Hayer S Ricci R David JP Tohidast-Akrad M Kollias G Steiner G Smolen JS Wagner EF Schett G Osteoclasts are essential for TNF-alpha-mediated joint destruction J Clin Invest 2002, 110:1419-1427. 151809 12438440
12. Teitelbaum SL Bone resorption by osteoclasts Science 2000, 289:1504-1508. 10.1126/science.289.5484.1504 10968780
13. Ritchlin CT Haas-Smith SA Li P Hicks DG Schwarz EM Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 2003, 111:821-831. 153764 12639988
14. Herman S Mueller R Kronke G Zwerina J Redlich K Hueber A Gelse H Neumann E Mueller-Ladner Schett G OSCAR, a key co-stimulation molecule for osteoclasts, is induced in patients with rheumatoid arthritis Arthritis Rheum 2009, 19116912
15. Zaiss MM Axmann R Zwerina J Polzer K Gückel E Skapenko A Schulze-Koops H Horwood N Cope A Schett G Treg cells suppress osteoclast formation: A new link between the immune system and bone Arthritis Rheum 2007, 56:4104-4112. 10.1002/art.23138 18050211
16. Axmann R Herman S Zaiss M Franz S Polzer K Zwerina J Herrmann M Smolen J Schett G CTLA-4 directly inhibits osteoclast formation Ann Rheum Dis 2008, 67:1603-1609. 10.1136/ard.2007.080713 18203760
17. Sato K Suematsu A Okamoto K Yamaguchi A Morishita Y Kadono Y Tanaka S Kodama T Akira S Iwakura Y Cua DJ Takayanagi H Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction J Exp Med 2006, 203:2673-2682. 2118166 17088434 10.1084/ jem.20061775
18. Gravallese EM Manning C Tsay A Naito A Pan C Amento E Goldring SR Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor Arthritis Rheum 2000, 43:250-258. 10.1002/ 1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P 10693863
19. Shigeyama Y Pap T Kunzler P Simmen BR Gay RE Gay S Expression of osteoclast differentiation factor in rheumatoid arthritis Arthritis Rheum 2000, 43:2523-2530. 10.1002/ 1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z 11083276
20. Stolina M Adamu S Ominsky M Dwyer D Asuncion F Geng Z Middleton S Brown H Pretorius J Schett G Bolon B Feige U Zack D Kostenuik PJ RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis J Bone Miner Res 2005, 20:1756-1765. 10.1359/ JBMR.050601 16160733
21. Cohen SB Dore RK Lane NE Ory PA Peterfy CG Sharp JT Heijde van der D Zhou L Tsuji W Newmark R Denosumab Rheumatoid Arthritis Study Group Denosumab treatment effects on structural damage, bone mineral density and bone turover in rheumatoid arthritis Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417 18438830
22. Seitz M Loetscher P Fey MF Tobler A Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients Br J Rheumatol 1994, 33:613-619. 10.1093/ rheumatology/33.7.613 8019788
23. Lam J Takeshita S Barker JE Kanagawa O Ross FP Teitelbaum SL TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J Clin Invest 2000, 106:1481-1488. 387259 11120755 10.1172/JCI11176
24. Klareskog L Heijde van der D de Jager JP Gough A Kalden J Malaise M Martín Mola E Pavelka K Sany J Settas L Wajdula J Pedersen R Fatenejad S Sanda M TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 2004, 363:675-681. 10.1016/ S0140-6736(04)15640-7 15001324
25. Smolen JS Heijde Van Der DM St Clair EW Emery P Bathon JM Keystone E Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial Arthritis Rheum 2006, 54:702-710. 10.1002/art.21678 16508926
26. Keystone EC Kavanaugh AF Sharp JT Tannenbaum H Hua Y Teoh LS Fischkoff SA Chartash EK Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized placebo-controlled 52-week trial Arthritis Rheum 2004, 50:1400-1411. 10.1002/art.20217 151464
27. Lipsky PE Heijde van der DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Harriman GR Maini RN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202 11096166
28. Weinblatt ME Keystone EC Furst DE Moreland LW Weisman MH Birbara CA Teoh LA Fischkoff SA Chartash EK Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Arthritis Rheum 2003, 48:35-45. 10.1002/art.10697 12528101
29. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Lipsky P Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group Lancet 1999, 354:1932-1939. 10.1016/ S0140-6736(99)05246-0 10622295
30. Maini RN Taylor PC Szechinski J Pavelka K Bröll J Balint G Emery P Raemen F Petersen J Smolen J Thomson D Kishimoto T CHARISMA Study Group Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 2006, 54:2817-2829. 10.1002/art.22033 16947782
31. Smolen JS Beaulieu A Rubbert-Roth A Ramos-Remus C Rovensky J Alecock E Woodworth T Alten R OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5 18358926
32. Wong PK Quinn JM Sims NA van Nieuwenhuijze A Campbell IK Wicks IP Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis Arthritis Rheum 2006, 54:158-168. 10.1002/art.21537 16385511
33. McQueen FM Gao A Østergaard M King A Shalley G Robinson E Doyle A Clark B Dalbeth N High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone Ann Rheum Dis 2007, 66:1581-1587. 10.1136/ard.2007.070326 17491098
34. Conaghan P Bird P Ejbjerg B O'Connor P Peterfy C McQueen F Lassere M Emery P Shnier R Edmonds J Østergaard M The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: The metacarpophalangeal joints Ann Rheum Dis 2005, 64:i11-i21. 1766829 15647417 10.1136/ ard.2004.031815
35. McQueen FM Benton N Perry D Crabbe J Robinson E Yeoman S McLean L Stewart N Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis Arthritis Rheum 2003, 48:1814-1827. 10.1002/art.11162 12847674
36. Jimenez-Boj E Redlich K Turk B Hanslik-Schnabel B Wanivenhaus A Chott A Smolen JS Schett G Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis J Immunol 2005, 175:2579-2588. 16081832
37. Güler-Yüksel M Bijsterbosch J Goekoop-Ruiterman YP de Vries-Bouwstra JK Ronday HK Peeters AJ de Jonge-Bok JM Breedveld FC Dijkmans BA Allaart CF Lems WF Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis Ann Rheum Dis 2007, 66:1508-1512. 10.1136/ard.2007.070839 17456523
38. Schett G Kiechl S Weger S Pederiva A Mayr A Petrangeli M Oberhollenzer F Lorenzini R Redlich K Axmann R Zwerina J Willeit J High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck study Arch Intern Med 2006, 166:2495-2501. 10.1001/archinte.166.22.2495 17159016
39. Kanis JA Johnell O Oden A Johansson H McCloskey E FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 2008, 19:385-397. 2267485 18292978 10.1007/ s00198-007-0543-5
40. van Staa TP Geusens P Bijlsma JW Leufkens HG Cooper C Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis Arthritis Rheum 2006, 54:3104-3101. 10.1002/art.22117 17009229
41. Diarra D Stolina M Polzer K Zwerina J Ominsky MS Dwyer D Korb A Smolen J Hoffmann M Scheinecker C Heijde van der D Landewe R Lacey D Richards WG Schett G Dickkopf-1 is a master regulator of joint remodeling Nat Med 2007, 13:156-163. 10.1038/nm1538 17237793
42. Glass DA Bialek P Ahn JD Starbuck M Patel MS Clevers H Taketo MM Long F McMahon AP Lang RA Karsenty G Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Dev Cell 2005, 8:751-764. 10.1016/j.devcel.2005.02.017 15866165
43. Sieper J Appel H Braun J Rudwaleit M Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes Arthritis Rheum 2008, 58:649-656. 10.1002/art.23260 18311819
44. Benjamin M McGonagle D The anatomical basis for disease localization in seronegative spondylarthropathy at entheses and related sites J Anat 2001, 199:503-526. 1468363 11760883 10.1046/j.1469-7580.2001.19950503.x
45. Lories RJ Derese I Luyten FP Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis J Clin Invest 2005, 115:1571-1579. 1090472 15902307 10.1172/JCI23738
46. Manz RA Arce S Cassese G Hauser AE Hiepe F Radbruch A Humoral immunity and long-lived plasma cells Curr Opin Immunol 2002, 14:517-521. 10.1016/ S0952-7915(02)00356-4 12088688
47. Tokoyoda K Egawa T Sugiyama T Choi BI Nagasawa T Cellular niches controlling B lymphocyte behavior within bone marrow during development Immunity 2004, 20:707-718. 10.1016/j.immuni.2004.05.001 15189736
48. Erickson LD Lin LL Duan B Morel L Noelle RJ A genetic lesion that arrests plasma cell homing to the bone marrow Proc Natl Acad Sci USA 2003, 100:12905-12910. 240717 14555759 10.1073/pnas.2131686100